Exhibit 24

DOCKET A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Cased 12.22: 0:000066-IT-SEKUPPM DDccommenter 6242 - Eifert SUBA017/23 Pagel 24/2562 Pagel D #: 29030 Pagel D #: 29030

Page 1 1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA 2 AT CLARKSBURG ----- x 3 REGENERON PHARMACEUTICALS, INC., 4 Plaintiff, 5 Case No. 1:22-cv-00061-TSK -versus-6 MYLAN PHARMACEUTICALS INC., 7 Defendant. 8 ----- x 9 10 11 ***HIGHLY CONFIDENTIAL*** 12 13 January 18, 2023 9:12 a.m. 14 15 16 VIDEOTAPED DEPOSITION of GEORGE D. 17 YANCOPOULOS, taken pursuant to Notice, held at Westchester Marriott, 670 White Plains Road, 18 19 Tarrytown, New York, before Fran Insley, a 20 Notary Public of the States of New York and New 21 Jersey. 22 23 24 25

Cased 1222:v:000616-17-56K/JPMM DDccommenter 62482-12/0et 50194017/23 Praigel 34/25623PaBeljDe #2 48560 Pagel D #: 29031

	Page 2		Page
1	APPEARANCES:	1	I N D E X
2	WILLIAMS & CONNOLLY	2	WITNESS EXAMINATION BY PAGE
3	Attorneys for Plaintiff and	3	GEORGE YANCOPOULOS MS. MAZZOCHI 7
4	Witness	4	
5	680 Maine Avenue, S.W.	5	EXHIBITS
6	Washington, D.C. 20024	6	DEPOSITION DESCRIPTION PAGE
7	BY: DAVID BERL, ESQ.	7	Exhibit 900 Objections to Interrogatories 51
8	ELLEN OBERWETTER, ESQ.	8	Exhibit 901 RGN-EYLEA-MYLAN00487461 to 503 54
9	-and-	9	Exhibit 902 RGN-EYLEA-MYLAN0054862 to 863 68
10	KATHRYN KAYALI, ESQ.	10	Exhibit 903 MYL-AFL5190 through 5215 75
11		11	Exhibit 904 MYL-AFL5216 through 5241 75
12	CAREY DOUGLAS KESSLER & RUBY PLLC		
13	Attorneys for Plaintiff	13	
14	707 Virginia Street East	14	(The following exhibits were not referred to in
15	901 Chase Tower		the deposition:
16	Charleston, West Virginia 25301		Exhibit 906 MYL-AFL90927 through 953
17	BY: DAVID R. POGUE, ESQ.		Exhibit 907 MYL-AFL90954 through 980
18	(via teleconference)		Exhibit 908 MYL-AFL91108
19	drpogue@cdkrlaw.com		Exhibit 909 RGN-EYLEA-MYLAN13557 through
20	- r · 3 ···()······		13602)
21			Exhibit 910 RGN-EYLEA-MYLAN13909 to 917 119
22			Exhibit 911 RGN-EYLEA-MYLAN13628 to 629 121
23			Exhibit 912 RGN-EYLEA-MYLAN13918 to 929 125
24			Exhibit 913 RGN-EYLEA-MYLAN525081 TO 083 133
25			Exhibit 914 MYL-AFL91250 to 273 139
1	Page 3	1	Page DEPOSITION DESCRIPTION DAGE
2	A P P E A R A N C E S : (Continued) RAKOCZY MOLINO MAZZZOCHI SIWIK LLP		DEPOSITION DESCRIPTION PAGE Exhibit 915 RGN-EYLEA-MYLAN501236 to 248 153
3	Attorneys for Defendant		Exhibit 916 RGN-EYLEA-MYLAN493989 to 994 179
3 4	6 West Hubbard Street		Exhibit 917 RGN-EYLEA-MYLAN504690 to 693 187
5	Suite 500		Exhibit 917 KON-ETLEA-MTLAN504090 to 053 187 Exhibit 918 RGN-EYLEA-MYLAN495807 to 852 203
5	Chicago, Illinois 60654		Exhibit 918 KGN-ETLEA-MTLAN493807 to 852 203 Exhibit 919 RGN-EYLEA-MYLAN539067 to 068 206
7	BY: DEANNE MAZZOCHI, ESQ.	7	
8	LAUREN LESKO, ESQ.	· ·	Exhibit 520A Previously marked 197
。 9			•
10	-and-		Exhibit 4 '601 Patent 24 Exhibit 5 '572 Patent 24
	JEFFREY A. MARX, ESQ.		
11	(via teleconference)	11	
12	jmarx@rmmslegal.com	12	
13	AND STEPTOE & IOLINISON I L B	13	
14	STEPTOE & JOHNSON, LLP	14	
15	400 White Oaks Boulevard	15	
16	Bridgeport, West Virginia 26330	16	
17	BY: WILLIAM J. O'BRIEN, ESQ.	17	
18 30	(via teleconference)	18	
19	jamie.obrien@steptoe-johnson.com	19	
20		20	
	ALSO PRESENT:	21	
22	LARRY COURY, ESQ., Regeneron	22	
	BAATTERRAW CERTNER Wideowenham	23	
23	MATTHEW CHIN-QUEE, Videographer		
23 24 25		24 25	

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Cased 122-2-vc-000616-17-56 KHPPM DDccommenter 62432-1216et 5094017/23 Pagel 040/25623Pagel 12: 48561 Pagel D #: 29032

Page 6	Page
1 THE VIDEOGRAPHER: Good morning. We 9:12:18AM	Q Have you given any statements or 9:14:26AM
2 are going on the record at 9:12 a.m. on 9:12:19AM	2 sworn testimony in any matter involving the US 9:14:30AM
3 January 18, 2023. 9:12:23AM	3 government and EYLEA? 9:14:33AM
4 This is media unit one of the 9:12:26AM	4 A. No, I have not. 9:14:40AM
5 videotaped deposition of George 9:12:29AM	5 Q. Have you given any statements or 9:14:41AM
6 Yancopoulos in the matter Regeneron 9:12:31AM	6 testimony involving any claims involving a 9:14:44AM
7 Pharmaceuticals Inc. v Mylan 9:12:35AM	7 state government relating to kickback 9:14:47AM
8 Pharmaceuticals Inc. et. al. Case number 9:12:38AM	8 allegations involving EYLEA? 9:14:49AM
9 1:22-CV-00061-TSK. The deposition is 9:12:42AM	9 A. No, I have not. 9:14:55AM
10 being held at 670 White Plains Road, 9:12:52AM	10 Q. Have you received any subpoenas to 9:14:56AM
11 Tarrytown, New York. 9:12:57AM	11 appear before a state or federal grand jury? 9:14:58AM
12 My name is Matthew Chin-Quee from 9:13:01AM	12 A. No, I have not. 9:15:04AM
13 Veritext and I'm the videographer. The 9:13:04AM	13 Q. Have you had any discussions 9:15:05AM
14 court reporter is Fran Insley from the 9:13:07AM	14 internally regarding the US Government's 9:15:06AM
15 fim Veritext. 9:13:09AM	15 kickback lawsuit against Regeneron involving 9:15:09AM
16 Will all counsel please state your 9:13:11AM	16 EYLEA? 9:15:12AM
17 appearances. 9:13:13AM	17 MR. BERLE: Objection. You can 9:15:13AM
18 MS. MAZZOCHI: Good morning. My 9:13:14AM	18 answer that yes or no. 9:15:15AM
19 name is Deanne Mazzochi from the law firm 9:13:15AM	19 A. I am not sure if I heard of anything 9:15:22AM
20 of Rakoczy Molio Mazzochi Siwik, LLP. 9:13:17AM	20 referred to in the manner in which you just 9:15:24AM
21 Also with me is Lauren Lesko. 9:13:19AM	21 described it. 9:15:27AM
22 MR. BERL: David Berl, Williams & 9:13:23AM	22 Q. Are you aware of or have you spoken 9:15:29AM
23 Connolly on behalf of Regeneron and the 9:13:24AM	23 to anyone internally within Regeneron involving 9:15:31AN
24 witness. With me are Ellen Oberwetter 9:13:27AM	24 allegations by the US Government that of 9:15:35AM
25 from Williams & Connolly and Kathryn 9:13:30AM	25 Regeneron's misuse of the Chronic Disease Fund 9:15:39A
Page 7	Page
1 Kayali from Williams & Connolly and Larry 9:13:32AM	1 or improper payments by Regeneron to the 9:15:43AM
2 Coury from Regeneron. 9:13:37AM	2 Chronic Disease Fund? 9:15:45AM
3 THE VIDEOGRAPHER: Will the court 9:13:39AM	3 MR. BERL: Objection. You can 9:15:49AM
4 reporter please swear in the witness. 9:13:40AM	4 answer that yes or no. 9:15:49AM
5 GEORGE YANCOPOULOS, the 9:13:41AM	5 A. Fm not sure that anything that Fm 9:15:55AM
6 Witness herein, having first been duly swom by 9:13:41AM	6 aware of has been referred to in that way that 9:15:57AM
7 the Notary Public, was examined and testified 9:13:41AM	7 you referred to it. 9:16:00AM
8 as follows: 9:13:41AM	8 Q. What is your understanding of the 9:16:02AM
9 EXAMINATION BY MS. MAZZOCHI: 9:13:49AM	9 Chronic Disease Fund? 9:16:03AM
10 Q. Good morning, Dr. Yancopoulos. Can 9:13:50AM	10 A. I'm not an expert in this matter. 9:16:10AM
11 you please state your full name and address for 9:13:52AM	11 Q. It doesn't matter. I'm not asking 9:16:11AM
12 the record? 9:13:54AM	12 for your expertise. I'm just asking for your 9:16:13AM
13 A George Damis Yancopoulos. 9:13:54AM	13 factual knowledge about the Chronic Disease 9:16:16AM
14 Q. Address? 9:13:57AM	14 Fund. 9:16:17AM
15 A Home address? 9:13:59AM	15 A. Factual knowledge? 9:16:21AM
16 Q. Sure. 9:14:00AM	16 Q. Right. 9:16:23AM
Regeneron Protected Material	17 A. I'm not sure if I understand. 9:16:25AM
	18 Q. Do you know what the Chronic Disease 9:16:28AM
19 Q. Have you given testimony under oath 9:14:09AM	19 Fund is? 9:16:29AM
20 before? 9:14:11AM	20 A. I believe the Chronic Disease Fund 9:16:40AM
21 A. No. 9:14:13AM	21 is a foundation that pays for the co-payments 9:16:42AM
21 28. HU. 9.14.1271W	22 for contain modicines when nationts connet 0.16.40 M
21 A. NO. 9:14:15AM 22 Q. Are you aware of the US Department 9:14:14AM	22 for certain medicines when patients cannot 9:16:49AM
22 Q. Are you aware of the US Department 9:14:14AM	22 for certain medicines when patients cannot 9.16.49AIM 23 afford to pay for them. 9:16:58AM
22 Q. Are you aware of the US Department 9:14:14AM	_

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Cased 1222:v:000616-17-56K/JPMM DDccommenen62482-1216et50194017/23 Praigel 94/125623PaBel(1)2#3: 48562 Pagel D #: 29033

		Page 10		Page 1
	•	9:17:06AM	1 the lawsuits, but I don't know if that was	9:20:09AM
2	*	9:17:08AM	2 involved in his leaving from the company.	9:20:12AM
3	A. I'm not personally aware of	9:17:15AM	3 Q. Do you have an understanding that	9:20:16AM
			4 Murray Goldberg was involved with some o	
	I believe that we provide donations to that	9:17:22AM		20:20AM
				22AM
7	Q. Do you know the size and scope of	9:17:30AM	7 Q. How about your CEO Len Schleifer	? 9:20:23AM
	the donations that Regeneron has provided to	9:17:33AM		28AM
-		:35AM	9 Q. Can you state your educational	9:20:30AM
0	•	37AM	10 background post high school?	9:20:31AM
1	Q. Do you know why Regeneron made	9:17:38AM	11 A. I received an undergraduate degree	9:20:39AM
2	donations to that foundation?	9:17:39AM	12 from Columbia College. I received medical	and 9:20:41AN
3	A. My understanding is so that the	9:17:44AM	13 Ph.D. degrees from Columbia as well.	9:20:49AM
	foundation can help pay the co-payments for	9:17:47AM	14 Q. How is it that you came to be	9:20:54AM
15	patients below a certain poverty level who	9:17:53AM	15 involved with Regeneron around the 1989 ti	me 9:20:57AN
6	cannot afford to pay for the co-payments for	9:17:57AM	16 period I think? 9:21	1:01AM
7	those medicines themselves.	9:18:00AM	17 A. I was approached by Leonard	9:21:04AM
8	Q. Do you have an understanding that	9:18:05AM	18 Schleifer who had interacted with my Ph.D.	9:21:10AM
9	Regeneron spent tens of millions of dollars in	9:18:06AM	19 mentor about the possibility of helping start	9:21:16AM
0	grants to that foundation? 93	18:11AM	20 this new company. 9	:21:23AM
:1	A. I really do not know the amounts	9:18:15AM	21 Q. Who was your Ph.D. mentor?	9:21:24AM
2	that we have donated to that foundation.	9:18:17AM	22 A. Fred Alt. 9:21	:29AM
3	Q. Who are the individuals you most	9:18:20AM	Q. What was the subject of your Ph.D.	9:21:30AM
:4	closely associate with Regeneron as	9:18:22AM	24 thesis? 9:21:3-	4AM
:5	understanding Regeneron's interaction with th	e 9:18:24AM	25 A. The molecular biology of lymphocy	te 9:21:45AM
		Page 11		Page :
1	Chronic Disease Fund and the foundation that	9:18:30AM	1 cell development. 9:	21: 49AM
2	operates it? 9:18:33	AM		
		1111	2 Q. What about your educational and	9:21:52AM
3	A. Well, I would so I believe the	9:18:35AM	 Q. What about your educational and Ph.D. work caused Mr. Schleifer to think you 	
			• •	u 9:21:56AM
4	A. Well, I would so I believe the	9:18:35AM	3 Ph.D. work caused Mr. Schleifer to think yo4 would be a good fit for what he was trying to	u 9:21:56AM
4 5	A. Well, I would so I believe the case that you are referring to is referring to	9:18:35AM 9:18:43AM	3 Ph.D. work caused Mr. Schleifer to think yo4 would be a good fit for what he was trying to	u 9:21:56AM o 9:22:03AM
4 5 6	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM	 3 Ph.D. work caused Mr. Schleifer to think yo 4 would be a good fit for what he was trying to 5 do with Regeneron? 	u 9:21:56AM o 9:22:03AM 9:22:05AM
4 5 6 7	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody i	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 	u 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM
4 5 6 7 8	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. 9	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 	au 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM at 9:22:25AM
4 5 6 7 8 9	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. 9 Q. Like Robert Terifay?	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM :19:04AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 	m 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36
4 5 7 8 9 0	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. 9 Q. Like Robert Terifay?	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM :19:04AM :19:06AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the component of what the	a 9:21:56AM 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM
4 5 6 7 8 9 0	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody i our commercial group. Q. Like Robert Terifay? 9 A. I do not know. 9:19 Q. When was the last time you spoke	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM 19:04AM 19:06AM 10AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the control would be trying to do, particularly clone nertice 	a 9:21:56AM 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM
4 5 6 7 8 9 0 1 2	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. 9 Q. Like Robert Terifay? 9 A. I do not know. 9:19 Q. When was the last time you spoke with Robert Terifay? 9:19	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM :19:04AM :19:06AM :10AM 9:19:12AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the co 10 would be trying to do, particularly clone neroing 11 growth factors that control nerve growth and 	a 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM d 9:22:46AM 9:22:54AM
4 5 6 7 8 9 0 1 2 3	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. Q. Like Robert Terifay? 9 A. I do not know. 9:19 Q. When was the last time you spoke with Robert Terifay? 9:19	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM :19:04AM :19:06AM :10AM 9:19:12AM 9:13AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the co 10 would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 	m 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM at 9:22:40AM at 9:22:40AM at 9:22:54AM
4 5 6 7 8 9 0 1 2 3 4	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. Q. Like Robert Terifay? 9 A. I do not know. 9:19 Q. When was the last time you spoke 9:19 A. I don't know. 9:19	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM 19:04AM 19:06AM 19:06AM 9:19:12AM 9:13AM 22AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the control would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 	m 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM at 9:22:40AM at 9:22:40AM at 9:22:54AM
4 5 6 7 8 9 0 1 2 3 4 5	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. Q. Like Robert Terifay? 9 Q. Like Robert Terifay? 9 Q. When was the last time you spoke 9:19 Q. When was the last time you spoke 9:19 Q. Are you aware of the reasons why 9:19	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM 19:04AM 19:06AM 19:06AM 9:19:12AM 9:13AM 22AM 9:19:24AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the co 10 would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve grow 	au 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM at 9:22:46AM 9:22:54AM 9:22:54AM vin 9:22:57AM vin 9:23:07AM
4 5 6 7 8 9 0 1 2 3 4 5 6	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody i our commercial group. Q. Like Robert Terifay? Q. Like Robert Terifay? Q. When was the last time you spoke with Robert Terifay? 9:19 Q. When was the last time you spoke with Robert Terifay? 9:19 Q. A. I don't know. 9:19: Q. Are you aware of the reasons why Mr. Terifay left the company?	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM 9:19:00AM 19:04AM 19:06AM 19:06AM 9:19:12AM 9:13AM 22AM 9:19:24AM 9:19:24AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the co 10 would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve grow 15 factor identified and the dream was to try to 	au 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36AM ve 9:22:46AM 9:22:54AM 9:22:54AM 5:in 9:22:57AM vth 9:23:04AM 9:23:07AM 9:23:15AM
4 5 6 7 8 9 0 1 2 3 4 5 6 7	 A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. Q. Like Robert Terifay? Q. Like Robert Terifay? Q. When was the last time you spoke with Robert Terifay? Q. Are you aware of the reasons why Mr. Terifay left the company? A. I am aware of some of the reasons. 	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM 9:19:00AM 19:04AM 19:06AM 10AM 9:19:12AM 9:19:12AM 9:13AM 22AM 9:19:24AM 9:19:26AM 9:19:32AM 9:19:32AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was the 9 would be a major component of what the co 10 would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve growth 15 factor identified and the dream was to try to 16 clone many more and then use them to help 	au 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36AM ve 9:22:46AM 9:22:54AM 9:22:54AM 5:in 9:22:57AM vth 9:23:04AM 9:23:07AM 9:23:15AM
456789012345678	 A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. Q. Like Robert Terifay? Q. Like Robert Terifay? Q. When was the last time you spoke with Robert Terifay? Q. Are you aware of the reasons why Mr. Terifay left the company? A. I am aware of some of the reasons. Q. What are some of the reasons you're 	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM 9:19:00AM 19:04AM 19:06AM 10AM 9:19:12AM 9:19:12AM 9:13AM 22AM 9:19:24AM 9:19:26AM 9:19:32AM 9:19:32AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was the 9 would be a major component of what the control would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve growth 15 factor identified and the dream was to try to 16 clone many more and then use them to help 17 either grow or sustain neurons that were dying 	a 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36A ve 9:22:40AM 1 9:22:54AM 9:22:54AM 9:22:57AM vin 9:22:57AM vin 9:22:04AM 9:23:07AM 9:23:15AM ng 9:23:22AM
4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9	 A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody i our commercial group. Q. Like Robert Terifay? Q. Like Robert Terifay? Q. When was the last time you spoke with Robert Terifay? Q. Are you aware of the reasons why Mr. Terifay left the company? A. I am aware of some of the reasons. Q. What are some of the reasons you're aware of? Q. I know that he had a number of 	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM 9:19:00AM 19:04AM 19:06AM 19:06AM 19:06AM 9:19:12AM 9:13AM 22AM 9:19:24AM 9:19:24AM 9:19:32AM 9:19:34AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the co 10 would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve growth 15 factor identified and the dream was to try to 16 clone many more and then use them to help 17 either grow or sustain neurons that were dying 18 in neurodegenerative diseases. 	a 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM 1 9:22:54AM 9:22:54AM 9:22:57AM vih 9:22:57AM vih 9:23:07AM 9:23:15AM 9:23:22AM ng 9:23:27AM
4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0	 A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. Q. Like Robert Terifay? Q. Like Robert Terifay? Q. When was the last time you spoke with Robert Terifay? Q. Are you aware of the reasons why Mr. Terifay left the company? A. I am aware of some of the reasons. Q. What are some of the reasons you're aware of? 9:19:36 A. I know that he had a number of catastrophic medical events such as multiple 	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM 9:19:00AM 19:04AM 19:06AM 19:06AM 20AM 9:19:12AM 9:19:12AM 9:19:24AM 9:19:26AM 9:19:26AM 9:19:32AM 9:19:34AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was the 9 would be a major component of what the co 10 would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve grow 15 factor identified and the dream was to try to 16 clone many more and then use them to help 17 either grow or sustain neurons that were dying 18 in neurodegenerative diseases. 19 In order to do that, one would have 20 to bring gene cloning in a big way into the 	au 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36 ve 9:22:40AM at 9:22:54AM 9:22:54AM 9:22:57AM vth 9:22:57AM vth 9:23:07AM 9:23:07AM 9:23:22AM 9:23:27AM 9:23:27AM 9:23:31AM 9:23:31AM
4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. 9 Q. Like Robert Terifay? 9 A. I do not know. 9:19 Q. When was the last time you spoke with Robert Terifay? 9:14 A. I don't know. 9:19: Q. Are you aware of the reasons why Mr. Terifay left the company? A. I am aware of some of the reasons. Q. What are some of the reasons. Q. What are some of the reasons you're aware of? 9:19:36 A. I know that he had a number of catastrophic medical events such as multiple strokes that affected his ability to come to	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM 19:04AM 19:06AM 19:06AM 10AM 9:19:12AM 9:19:12AM 9:19:24AM 9:19:26AM 9:19:32AM 9:19:32AM 9:19:32AM 9:19:32AM 9:19:40AM 9:19:42AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was the 9 would be a major component of what the control would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve growth 15 factor identified and the dream was to try to 16 clone many more and then use them to help 17 either grow or sustain neurons that were dyit 18 in neurodegenerative diseases. 19 In order to do that, one would have 20 to bring gene cloning in a big way into the 21 field of neurobiology. There were not that 	a 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36A ve 9:22:40AM d 9:22:54AM 9:22:54AM 9:22:54AM 9:22:57AM vth 9:22:07AM 9:23:07AM 9:23:15AM 9:23:27AM 9:23:31AM 9:23:33AM 9:23:37AM
4 5 6 7 8 9 00 11 22 13 14 5 16 7 8 9 20 12 22 22 22 22 22 22 22 22 22 22 22 22	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. 9 Q. Like Robert Terifay? 9 A. I do not know. 9:19 Q. When was the last time you spoke with Robert Terifay? 9:19 A. I don't know. 9:19: Q. Are you aware of the reasons why Mr. Terifay left the company? A. I am aware of some of the reasons. Q. What are some of the reasons you're aware of? 9:19:30 A. I know that he had a number of catastrophic medical events such as multiple strokes that affected his ability to come to work. 9:19:54/	9:18:35AM 9:18:35AM 9:18:46AM 9:18:54AM 9:19:00AM 19:04AM 19:06AM 19:06AM 19:06AM 9:19:12AM 9:19:12AM 9:19:24AM 9:19:24AM 9:19:32AM 9:19:34AM 9:19:34AM 9:19:40AM 9:19:48AM 9:19:48AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was that 9 would be a major component of what the co 10 would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve growth 15 factor identified and the dream was to try to 16 clone many more and then use them to help 17 either grow or sustain neurons that were dying 18 in neurodegenerative diseases. 19 In order to do that, one would have 20 to bring gene cloning in a big way into the 21 field of neurobiology. There were not that 	au 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36AM ve 9:22:40AM 1 9:22:54AM vin 9:22:57AM vin 9:22:57AM vin 9:22:57AM 9:23:07AM 9:23:07AM 9:23:27AM 9:23:22AM 9:23:31AM 9:23:33AM 9:23:37AM 9:23:37AM
4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1	A. Well, I would so I believe the case that you are referring to is referring to issues back in 2013. I do not know who at Regeneron was largely responsible for interactions. I assume it would be somebody is our commercial group. 9 Q. Like Robert Terifay? 9 A. I do not know. 9:19 Q. When was the last time you spoke with Robert Terifay? 9:14 A. I don't know. 9:19: Q. Are you aware of the reasons why Mr. Terifay left the company? A. I am aware of some of the reasons. Q. What are some of the reasons. Q. What are some of the reasons you're aware of? 9:19:36 A. I know that he had a number of catastrophic medical events such as multiple strokes that affected his ability to come to	9:18:35AM 9:18:43AM 9:18:46AM 9:18:54AM n 9:19:00AM 19:04AM 19:06AM 19:06AM 10AM 9:19:12AM 9:19:12AM 9:19:24AM 9:19:26AM 9:19:32AM 9:19:32AM 9:19:32AM 9:19:32AM 9:19:40AM 9:19:42AM	 3 Ph.D. work caused Mr. Schleifer to think you 4 would be a good fit for what he was trying to 5 do with Regeneron? 6 MR. BERL: Objection. 7 A. At the time the field of cloning 8 genes was in its infancy and the idea was the 9 would be a major component of what the control would be trying to do, particularly clone ner 11 growth factors that control nerve growth and 12 could be used to fight back against 13 neurodegenerative diseases and to that point 14 time there had only been a single nerve growth 15 factor identified and the dream was to try to 16 clone many more and then use them to help 17 either grow or sustain neurons that were dyit 18 in neurodegenerative diseases. 19 In order to do that, one would have 20 to bring gene cloning in a big way into the 21 field of neurobiology. There were not that 	au 9:21:56AM o 9:22:03AM 9:22:05AM 9:22:06AM 9:22:06AM 9:22:10AM at 9:22:25AM mpany 9:22:36A ve 9:22:40AM 9:22:54AM 9:22:54AM 9:22:54AM 9:22:57AM 9:23:07AM 9:23:07AM 9:23:27AM 9:23:22AM 9:23:31AM 9:23:33AM 9:23:37AM 9:23:37AM any 9:23:44AM

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.